EpiCombi.AI ^Companies

EpiCombi.AI is a spinout from Oxford University that focuses on genomics signature-driven therapeutics. Their main goal is to overcome epigenetic barriers in cancer complexity through the development of AI-derived, network-acting multi-targeted drugs. EpiCombi.AI utilizes advanced technology and genomic data to create innovative solutions for cancer treatment. Their achievements include the development of groundbreaking therapies that target multiple pathways in cancer cells, offering new hope for patients with complex forms of the disease.